197 related articles for article (PubMed ID: 37568126)
21. Exploring the safety profile of tremelimumab: an analysis of the FDA adverse event reporting system.
Zhao Y; Jiang H; Xue L; Zhou M; Zhao X; Liu F; Jiang S; Huang J; Meng L
Int J Clin Pharm; 2024 Apr; 46(2):480-487. PubMed ID: 38245663
[TBL] [Abstract][Full Text] [Related]
22. Post-Marketing Safety of Vemurafenib: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System.
Liu Y; Dong C; He X; Shu Y; Wu P; Zou J
J Pharm Pharm Sci; 2022; 25():377-390. PubMed ID: 36608646
[TBL] [Abstract][Full Text] [Related]
23. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
[TBL] [Abstract][Full Text] [Related]
24. Disproportionality Analysis of Abemaciclib in the FDA Adverse Event Reporting System: A Real-World Post-Marketing Pharmacovigilance Assessment.
Shu Y; Wang L; Ding Y; Zhang Q
Drug Saf; 2023 Sep; 46(9):881-895. PubMed ID: 37418089
[TBL] [Abstract][Full Text] [Related]
25. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.
Sun R; Ning Z; Qin H; Zhang W; Teng Y; Jin C; Liu J; Wang A
Sci Rep; 2024 Apr; 14(1):9552. PubMed ID: 38664423
[TBL] [Abstract][Full Text] [Related]
26. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
Zhao D; Long X; Zhou J; Wang J
Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
[TBL] [Abstract][Full Text] [Related]
27. Adverse events of guselkumab in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
Xiang DC; Chen W; Fu ZW; Wu XH; Gao P; Wu Y
Expert Opin Drug Saf; 2023; 22(10):943-955. PubMed ID: 37294594
[TBL] [Abstract][Full Text] [Related]
28. Comparison of Online Patient Reviews and National Pharmacovigilance Data for Tramadol-Related Adverse Events: Comparative Observational Study.
Park S; Choi SH; Song YK; Kwon JW
JMIR Public Health Surveill; 2022 Jan; 8(1):e33311. PubMed ID: 34982723
[TBL] [Abstract][Full Text] [Related]
29. A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin.
Xu Z; Huang D; Liu Q; Liu S; Liu J; Wang H; Shen Z
Expert Opin Drug Saf; 2024 May; ():1-9. PubMed ID: 38695550
[TBL] [Abstract][Full Text] [Related]
30. Post-marketing safety concerns with palbociclib: a disproportionality analysis of the FDA adverse event reporting system.
Cheng Q; Shi X; Zhao Y; Zou S; Sun M
Expert Opin Drug Saf; 2024 May; 23(5):637-648. PubMed ID: 38564277
[TBL] [Abstract][Full Text] [Related]
31. Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database.
Li Z; Guo C; Liu X; Qiu Z; Zhang R
Front Pharmacol; 2024; 15():1368763. PubMed ID: 38549677
[No Abstract] [Full Text] [Related]
32. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
[TBL] [Abstract][Full Text] [Related]
33. Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System.
Huang J; Meng L; Yang B; Sun S; Luo Z; Chen H
Sci Rep; 2020 Mar; 10(1):4803. PubMed ID: 32179761
[TBL] [Abstract][Full Text] [Related]
34. Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
Shu Y; Ding Y; Liu Y; Wu P; He X; Zhang Q
Front Pharmacol; 2022; 13():862508. PubMed ID: 35754494
[No Abstract] [Full Text] [Related]
35. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
Liu W; Du Q; Guo Z; Ye X; Liu J
Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
[No Abstract] [Full Text] [Related]
36. Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database.
Sato K; Mano T; Iwata A; Toda T
Biosci Trends; 2020 May; 14(2):139-143. PubMed ID: 32321905
[TBL] [Abstract][Full Text] [Related]
37. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
[TBL] [Abstract][Full Text] [Related]
38. A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database.
Rong L; Xie M; Jiang M; Qiu H; Kong L
Br J Clin Pharmacol; 2023 Jan; ():. PubMed ID: 36702463
[TBL] [Abstract][Full Text] [Related]
39. A pharmacovigilance analysis of FDA adverse event reporting system events for romosozumab.
Chen Z; Li M; Li S; Li Y; Wu J; Qiu K; Yu X; Huang L; Chen G
Expert Opin Drug Saf; 2023 Apr; 22(4):339-342. PubMed ID: 36178002
[TBL] [Abstract][Full Text] [Related]
40. A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system.
Li H; Wang C; Deng A; Guo C
Front Pharmacol; 2023; 14():1280490. PubMed ID: 38143494
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]